A61K 31/661
Phosphorus acids or esters thereof not having p—c bonds
Official title: Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion {or mevinphos}
A61K31/661 (Phosphorus acids or esters thereof not having p—c bonds) appears on 891 US grants and 1,679 published applications in this corpus.
Search patents in A61K- Granted patents
- 891
- Published applications
- 1,679
- Assignees
- 820
- Inventors
- 2,900
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 1 | 0 |
| 1996 | 6 | 0 |
| 1997 | 4 | 0 |
| 1998 | 12 | 0 |
| 1999 | 22 | 0 |
| 2000 | 18 | 0 |
| 2001 | 12 | 2 |
| 2002 | 19 | 22 |
| 2003 | 14 | 22 |
| 2004 | 3 | 29 |
| 2005 | 8 | 25 |
| 2006 | 14 | 28 |
| 2007 | 8 | 30 |
| 2008 | 9 | 49 |
| 2009 | 4 | 54 |
| 2010 | 20 | 61 |
| 2011 | 21 | 53 |
| 2012 | 20 | 56 |
| 2013 | 27 | 82 |
| 2014 | 39 | 96 |
| 2015 | 45 | 97 |
| 2016 | 48 | 91 |
| 2017 | 61 | 115 |
| 2018 | 67 | 81 |
| 2019 | 61 | 86 |
| 2020 | 46 | 80 |
| 2021 | 40 | 103 |
| 2022 | 63 | 110 |
| 2023 | 55 | 107 |
| 2024 | 48 | 83 |
| 2025 | 51 | 54 |
| 2026 | 24 | 63 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin6 Oct 2026US 12,751,960 B2Compass Pathfinder Limited
- Nutritional formulas comprising medium chain fatty acids or esters thereof and methods related thereto15 Sep 2026US 12,734,145 B2Children's Healthcare of Atlanta, Inc.
- Clinical dosing schedule of inositol phosphate oligo(ethylene glycol) compounds15 Sep 2026US 12,734,184 B2Vifor (International) AG
- Disinfectant composition with rapid antiviral efficacy8 Sep 2026US 12,728,177 B2Kimberly-Clark Worldwide, Inc.
- Psilocybin compositions, methods of making and methods of using the same1 Sep 2026US 12,721,856 B2Compass Pathfinder Limited
- Method of inhibiting adenosine triphosphate secretion, method of inhibiting hepatic stellate cell activation, method of deactivating hepatic stellate cell, method of treating hepatic fibrosis, method of treating non-alcoholic steatohepatitis, and method of treating psoriasis8 Oct 2026US 2026/0306500 A1Kurume University
- Subcutaneously administered treatments for advanced parkinson’s disease8 Oct 2026US 2026/0306517 A1AbbVie Inc.
- Psilocybin compositions, methods of making and methods of using the same1 Oct 2026US 2026/0294939 A1Compass Pathfinder Limited
- Pharmaceutically active compositions and uses thereof24 Sep 2026US 2026/0283965 A1Xerient Pharma Ltd.
- Cysteamine for the treatment, mitigation and prevention of coronaviral, e.g., sars-cov-2, infections17 Sep 2026US 2026/0272861 A1The Regents of the University of Michigan
Most cited
By later US patents
- Selective androgen receptor modulators and methods of use thereof113US 6,569,896 B2The University of Tennessee Research Corporation · 2003
- Inhibitors of NAALADase enzyme activity97US 5,795,877 AGuilford Pharmaceuticals Inc. · 1998
- Formulations comprising selective androgen receptor modulators85US 6,838,484 B2University of Tennessee Research Foundation · 2005
- Crystallization method and bioavailability84US 9,169,279 B2Thar Pharmaceuticals, Inc. · 2015
- Synthesis of selective androgen receptor modulators83US 6,995,284 B2University of Tennessee Research Foundation · 2006